Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AMGN34 | B3 | BRL | Delayed | |
AMGN | NASDAQ | USD | Real-time | |
AMGN | BIVA | MXN | Delayed | |
AMGN | Mexico | MXN | Delayed | |
AAMGN | Milan | EUR | Real-time | |
AMGN | Frankfurt | EUR | Delayed | |
AMGN | Xetra | EUR | Delayed | |
AMGN | TradeGate | EUR | Delayed | |
AMGNm | Buenos Aires | ARS | Delayed | |
AMGN | Vienna | EUR | Real-time | |
AMGN | Lima | USD | Delayed |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Name | Age | Since | Title |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
Tyler E. Jacks | 62 | 2012 | Independent Director |
David Baltimore | 85 | 1999 | Co-Chair of Scientific Advisory Board |
Charles M. Holley | 66 | 2017 | Independent Director |
Charles Elliott Sigal | 72 | - | Co-Chair of the Scientific Advisory Board |
Ellen J. Kullman | 68 | 2016 | Independent Director |
Robert A. Eckert | 70 | 2012 | Lead Independent Director |
Amy E. Miles | 57 | 2020 | Independent Director |
Wanda M. Austin | 70 | 2017 | Independent Director |
Greg C. Garland | 67 | 2013 | Independent Director |
Brian J. Druker | 68 | 2018 | Independent Director |
S. Omar Ishrak | 68 | 2021 | Independent Director |
Benoit Van den Eynde | - | - | Member of Scientific Advisory Board of Oncology |
David J. Anderson | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Ruslan Medzhitov | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Antoni Ribas | 57 | - | Member of Scientific Advisory Board of Oncology |
Peter Libby | 77 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Robert S. Negrin | - | - | Member of Scientific Advisory Board of Oncology |
Daniel P. Kelly | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Daniel Joshua Drucker | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Frank P. McCormick | 74 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Michael V. Drake | 73 | 2022 | Independent Director |
S. Gail Eckhardt | - | 2022 | Member of Scientific Advisory Board of Oncology |
Mary E. Klotman | - | 2024 | Director |
George Georgiou | 65 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Marlene Rabinovitch | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
David Alan Kass | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jonathan S. Weissman | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
E. Dale Abel | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board of Oncology |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Elizabeth McNally | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jeffery D. Molkentin | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Siwen Hu-Lieskovan | - | - | Member of Scientific Advisory Board of Oncology |
Drew Mark Pardoll | - | - | Member of Scientific Advisory Board of Oncology |
Ronald M. Evans | 75 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Dirk Jäger | - | - | Member of Scientific Advisory Board of Oncology |
Robert Tjian | 75 | - | Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies |
Thomas Quertermous | 72 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Fabrice Andre | - | - | Member of Scientific Advisory Board of Oncology |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review